Dendritic cells in the human vaginal mucosa can direct CD4+ T cell responses by expressing surface OX40L
Year: 2025
Type: article
Abstract: Introduction Immunity in the vaginal mucosa (VM) is of critical importance for the protection from infections and cancers. Dendritic cells (DCs) are the major antigen-presenting cells that can induce and control T cell responses. Interestingly, VM Langerhans cells (vLCs) and VM CD1c + CD14 - DCs (vDCs) polarize CD4 + T cells toward Th2-type. However, the mechanisms underlying Th2 polarization by vDCs remain unknown. Methods OX40L expression was determined in the human VM tissue sections, followed by the measurement of OX40L expression on vLCs, CD1c + CD14 - vDCs, and VM macrophages (vMØs) by flow cytometry. The roles of OX40L on vDC subsets in the induction of different types of CD4 + T cell responses were assessed. Results Both vLCs and CD1c + CD14 - vDCs express surface OX40L. Neutralizing OX40L with anti-OX40L antibody significantly decreased the frequency of Th2-type CD4 + T cells with a reduction of CD4 + T cell proliferation, while increasing the frequency of IL - 10-producing CD4 + T cell responses. Anti-OX40L did not affect vLC- or CD1c + CD14 - vDC-induced Th1-type T cell responses. OX40L also contributed to the induction of IL - 21 + CD4 + T cell responses by vLCs and CD1c + CD14 - vDCs. In contrast to vLCs and CD1c + CD14 - vDCs, vMØs expressed a minimal level of surface OX40L. Likewise, anti-OX40L did not significantly affect vMØ-induced CD4 + T cell responses. Conclusions OX40L contributes to vLC- and CD1c + CD14 - vDC-induced Th2 polarization. It also significantly affects the frequency of vLC- and CD1c + CD14 - vDC-induced IL - 10 + and IL - 21 + CD4 + T cells. This study provides new insights into the immunological landscape of the human VM tissues, with implications for the development of targeted immunomodulatory strategies at this mucosal site.
Source: Frontiers in Immunology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
Funder: National Institutes of Health
OpenAlex ID: W4413902132
